Predicting study duration in clinical trials with a time-to-event endpoint

被引:2
|
作者
Machida, Ryunosuke [1 ,2 ]
Fujii, Yosuke [3 ]
Sozu, Takashi [4 ]
机构
[1] Tokyo Univ Sci, Dept Informat & Comp Technol, Grad Sch Engn, Tokyo, Japan
[2] Natl Canc Ctr, Ctr Res Adm & Support, Biostat Div, Tokyo, Japan
[3] Pfizer R&D Japan GK, Biometr & Data Management, Tokyo, Japan
[4] Tokyo Univ Sci, Fac Engn, Dept Informat & Comp Technol, Tokyo, Japan
基金
日本学术振兴会;
关键词
clinical trial; prediction; sample size; study duration; time‐ to‐ event; FOLLOW-UP; SURVIVAL; RECRUITMENT; ENROLLMENT; COUNTS;
D O I
10.1002/sim.8911
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In event-driven clinical trials comparing the survival functions of two groups, the number of events required to achieve the desired power is usually calculated using the Freedman formula or the Schoenfeld formula. Then, the sample size and the study duration derived from the required number of events are considered; however, their combination is not uniquely determined. In practice, various combinations are examined considering the enrollment speed, study duration, and the cost of enrollment. However, effective methods for visually representing their relationships and evaluating the uncertainty in study duration are insufficient. We developed a graphical approach for examining the relationship between sample size and study duration. To evaluate the uncertainty in study duration under a given sample size, we also derived the probability density function of the study duration and a method for updating the probability density function according to the observed number of events (ie, information time). The proposed methods are expected to improve the operation and management of clinical trials with a time-to-event endpoint.
引用
收藏
页码:2413 / 2421
页数:9
相关论文
共 50 条
  • [31] Adjusting for centre heterogeneity in multicentre clinical trials with a time-to-event outcome
    Munda, Marco
    Legrand, Catherine
    PHARMACEUTICAL STATISTICS, 2014, 13 (02) : 145 - 152
  • [32] Sample sizes for clinical trials with time-to-event endpoints and competing risks
    Schulgen, G
    Olschewski, M
    Krane, V
    Wanner, C
    Ruf, G
    Schumacher, M
    CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 386 - 396
  • [33] Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
    Uno, Hajime
    Schrag, Deborah
    Kim, Dae Hyun
    Tang, Dejun
    Tian, Lu
    Rugo, Hope S.
    Wei, Lee-Jen
    JNCI CANCER SPECTRUM, 2019, 3 (04)
  • [34] Meta-analysis of clinical trials with competing time-to-event endpoints
    Meddis, Alessandra
    Latouche, Aurelien
    Zhou, Bingqing
    Michiels, Stefan
    Fine, Jason
    BIOMETRICAL JOURNAL, 2020, 62 (03) : 712 - 723
  • [35] An evaluation of statistical methods for predicting timelines for reaching target number of events in clinical trials with time-to-event endpoints
    Clark, Emma
    Helms, Hans-Joachim
    Stanzel, Sven
    Xia, Fan
    TRIALS, 2017, 18
  • [36] Local Time-to-Event Endpoint Under-Reporting and Variability in Pancreatic Cancer Trials Involving Radiotherapy
    Lin, T. A.
    Mao, S.
    Anker, C.
    Herman, J. M.
    Meyer, J. J.
    Narang, A.
    Hu, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E316 - E317
  • [37] Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint
    Bruckner, Matthias
    Titman, Andrew
    Jaki, Thomas
    STATISTICS IN MEDICINE, 2017, 36 (20) : 3137 - 3153
  • [38] Validation of a longitudinally measured surrogate marker for a time-to-event endpoint
    Renard, D
    Geys, H
    Molenberghs, G
    Burzykowski, T
    Buyse, M
    Vangeneugden, T
    JOURNAL OF APPLIED STATISTICS, 2003, 30 (02) : 235 - 247
  • [39] Bayesian optimal phaseIIclinical trial design with time-to-event endpoint
    Zhou, Heng
    Chen, Cong
    Sun, Linda
    Yuan, Ying
    PHARMACEUTICAL STATISTICS, 2020, 19 (06) : 776 - 786
  • [40] Estimating the Treatment Effect in a Subgroup Defined by an Early Post-Baseline Biomarker Measurement in Randomized Clinical Trials With Time-To-Event Endpoint
    Bornkamp, Bjoern
    Bermann, Georgina
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (01): : 19 - 28